Skip to content

F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer

Comparison of F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06789562
Enrollment
54
Registered
2025-01-23
Start date
2025-01-30
Completion date
2027-12-31
Last updated
2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

Is to compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

Detailed description

* The optimal treatment of non-small cell lung cancer (NSCLC) relies on accurate disease staging that is based on the TNM system which relies on tumor size, regional nodal involvement, and the presence of metastasis. * CT is the standard modality used to assess the intra-thoracic spread but false negative CT scans have been reported and were related to the presence of metastasis in normal sized lymph nodes and false positive findings have been related to lymph node enlargement due to benign process. PET is most widely used in thoracic oncology because of its superiority over other imaging techniques in staging nodal and metastatic disease, however, the poor anatomic details of PET can lead to errors in diagnosis and staging. • To solve this problem, CT is combined with PET to provide matched morphological and functional data. The diagnostic capability of PET/CT in the preoperative staging of lung cancer is superior to that of CT alone and PET alone as it has the advantage of a more accurate assignment of tumor stage (T stage) and defining the lymph node stage (N stage) as well as reduction of the number of useless thoracotomies

Interventions

DEVICEF-18FDG PET/CT and CT

compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients with pathologically proven NSCLC who underwent initial PET/CT images. * All patients ≥ 18 years.

Exclusion criteria

* Patients who had started treatment before initial PET/CT. Patients with glucose level \< 200 mg/dl. Patients with another malignant condition.

Design outcomes

Primary

MeasureTime frameDescription
compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.Baselinedetect added value of F-18FDG PET/CT .

Contacts

Primary ContactWalaa Gamal, assistant lecturer
dr.walaa196@gmail.com01065037395
Backup ContactNahla Moustafa, assistant professor
Nahla_bashank_2006@yahoo.com01009466255

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026